ModifiedUnitedHealthcarePolicy CS079TN.U

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Tennessee Only)

Policy governs medical necessity and coverage stance for minimally invasive procedures used to treat upper gastrointestinal diseases for Tennessee Medicaid and CoverKids members; it applies to providers seeking coverage for these procedures.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Tennessee Only)

Policy CodePolicy CS079TN.U

Change TypeMaterial coverage update — GES and pyloroplasty language addedfunctional lumen imaging probe NMN language removed

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization documenting failure of standard therapies and supporting diagnostic tests before requesting coverage for device-based or surgical interventions.

SourceLink

POLICY UPDATE CHANGES

Title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Tennessee Only)' to 'Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Tennessee Only)'.

Added reference link to the Drug Policy titled Botulinum Toxins A and B and related coverage rationale.

Gastric electrical stimulation (GES) therapy and surgical pyloroplasty are described as proven and medically necessary for refractory gastroparesis that has failed other therapies or chronic intractable nausea and vomiting of diabetic or idiopathic etiology.

Removed language indicating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing achalasia.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

≥1material changes affecting clinical coverage

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

policy title changes recorded

83%POEM 2-year success (Werner RCT)

89.6%POEM overall clinical success (meta-analysis)

61-86%pyloroplasty reported success range

151Enterra GES cohort size (single-center)

Coverage Criteria and Medical Necessity

GES (Covered)

Covered when ALL of the following are met for specific procedures:

GES medical necessity: Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Refer to the FDA section for device labeling/HDE information.

Pyloroplasty (Covered)

Pyloroplasty medical necessity: Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Evidence and surgical society reviews report improvement in symptoms and normalization of gastric emptying with pyloroplasty.

POEM (Covered indications)

POEM indication: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with achalasia or diffuse esophageal spasm.

Randomized trials and systematic reviews demonstrate noninferiority or superiority to other modalities for achalasia subtypes when performed by experienced operators.

POEM (Not covered indications)

POEM other indications: POEM is unproven and not medically necessary for all other indications (for example, Zenker's diverticula) due to insufficient evidence of efficacy and limited long-term comparative data.

Evidence for non-achalasia indications is limited and of low quality.

G-POEM (Not covered)

G-POEM stance: Gastric per oral endoscopic myotomy (G-POEM) is unproven and not medically necessary for the treatment of gastroparesis due to insufficient high-quality evidence of long-term safety and effectiveness.

Observed short-term benefit in some series but randomized and long-term comparative data are limited.

GERD endoscopic and implant therapies (Not covered / investigational)

GERD endoscopic/implant therapies: Endoscopic therapies, injection or implantation techniques, and the LINX Reflux Management System are unproven and not medically necessary for treating GERD when evidence of long-term efficacy and safety is insufficient.

Endoluminal therapy with GERDx is investigational and not FDA-approved; multiple device-specific evidence limitations cited.

GES — guideline contextual criteria

Guideline-based contextual criteria referenced in the evidence:

GES candidate: Patient has medically refractory diabetic or idiopathic gastroparesis with persistent symptoms after standard therapy, and is not using opioids; GES may be considered as a humanitarian use device per guideline statements.failure of standard therapy; opioid-free status where specified

Based on ACG (conditional, low-quality evidence) and AGA clinical practice update guidance.

Pyloroplasty — evidence summary

Surgical pyloroplasty considerations from systematic reviews and surgical society statements:

Pyloroplasty candidate: Patients with refractory gastroparesis may be considered for pyloroplasty; evidence reports variable success rates and some analyses suggest pyloric interventions offer more consistent symptom relief than GES.failure of medical therapy

SAGES and systematic reviews support laparoscopic pyloroplasty as an effective surgical option with high rates of normalized gastric emptying.

POEM — guideline and evidence-based context

POEM coverage-context criteria informed by trials and reviews:

POEM candidate: Patient diagnosed with achalasia (types I–III) where endoscopic myotomy is being considered; prior therapy and achalasia subtype should be documented; POEM has randomized trial evidence demonstrating noninferiority to laparoscopic Heller myotomy and favorable outcomes versus pneumatic dilation in certain settings.documented achalasia diagnosis and subtype

Werner RCT and multiple systematic reviews/meta-analyses support efficacy when performed by experienced operators.

Z-POEM — limited evidence

Z-POEM coverage-context considerations:

Z-POEM candidate: Patients with symptomatic Zenker's diverticulum may be considered for Z-POEM in expert centers, but evidence is limited and comparative long-term outcomes are uncertain.expert center selection and informed consent

Meta-analyses show comparable short-term outcomes to flexible endoscopic septotomy but long-term data are limited and studies are often retrospective.

Evidence-based coverage summaries

Coverage considerations based on current evidence:

Z-POEM: Evidence is insufficient — short-term comparative data exist but long-term safety, recurrence, and reintervention rates are uncertain; further high-quality studies are needed.limited long-term data

Multiple systematic reviews and observational studies show short-term comparability but with limitations.

G-POEM: Evidence shows potential benefit for refractory gastroparesis with roughly 70% one-year clinical success in pooled observational studies but overall evidence quality is low; randomized trial data are limited.low-quality evidence

Long-term durability and comparative effectiveness versus surgical pyloroplasty remain unclear.

Stretta (Radiofrequency for GERD): Evidence is low to very low quality with mixed results; a sham-controlled RCT did not show consistent benefit while other nonrandomized studies report symptom improvements; comparative effectiveness versus fundoplication is uncertain.

Coverage decision framework

Evidence-based coverage consideration should be structured around device-specific efficacy, patient selection, prior medical therapy, and durability of benefit.

General eligibility: Patient has documented GERD with objective evidence or validated symptom scores and has had an adequate trial of medical therapy (including PPI) or is PPI-dependent/refractory.documented abnormal pH monitoring or validated symptom scores; trial of PPI therapy

Supported by device trials and guideline references.

Device-specific evidence requirement: At least one of the following supportive evidence items is present: randomized or sham-controlled trial demonstrating symptom improvement, or large prospective series with clinically meaningful reduction in GERD-HRQL and PPI use with acceptable safety.trial-level supportive data

EFTP (Kalapala), TIF, MUSE and other device studies provide varying levels of evidence but with limitations.

Durability and follow-up:

Device-based GERD procedure coverage criteria (implied)

Coverage consideration for device-based GERD interventions when ALL of the following are met:

Patient selection: Chronic or refractory GERD with inadequate control on PPI therapy or documented intolerance to PPI; prior documented trial of PPI therapy is expected (many studies required at least 6 months of PPI use).clinical history and medication records showing PPI trial

Supported by TIF and LINX study inclusion criteria.

Objective testing and anatomic criteria: Objective testing such as abnormal pH monitoring/DeMeester score and assessment of hiatal hernia size (many trials required hiatal hernia ≤2–3 cm) and absence of advanced esophagitis or Barrett's when specified.documented abnormal pH/DeMeester and hiatal hernia measurement

Reflects inclusion criteria from TEMPO TIF trial and LINX RCTs.

Informed consent and understanding of risks:

Investigational / Not medically necessary

Not covered / considered investigational when ANY of the following apply:

Insufficient evidence devices: Plexiglas and Durasphere injectable techniques have insufficient evidence to establish safety and effectiveness; additional randomized studies are warranted.evidence limited to small case series

Explicitly stated insufficiency in the policy literature.

Unproven long-term safety: Devices lacking adequate long-term safety and durability data (for example, some LINX and TIF analyses) may be considered investigational when used outside study or established criteria.absence of long-term comparative data

Policy highlights need for longer-term RCTs and larger cohorts.

Endoscopic therapies lacking robust evidence: Endoscopic plication/suturing, injection, or other endoluminal procedures supported only by small, nonrandomized series without durable objective outcomes are considered investigational and not medically necessary.

Initial coverage for antireflux procedures (MSA/TIF/Stretta)

Covered when ALL of the following are met based on evidence and guideline recommendations

General coverage prerequisites: Documented objective evidence of GERD (for example, abnormal pH testing, endoscopic findings, manometry) AND persistent troublesome regurgitation or heartburn despite optimized medical therapy (including twice-daily PPI where studied).documented objective testing and failed medical therapy

Supported by RCTs and guideline recommendations for antireflux procedures.

Device/procedure-specific considerations: Device-specific FDA status and intended indications should align with the planned procedure (for example, LINX PMA labeling), and patient anatomy (for example, hiatal hernia ≤2–3 cm, absence of severe esophagitis or Barrett's esophagus for some devices) should be documented.device-specific FDA labeling and anatomic documentation

Referenced in trial eligibility, SAGES and ASGS guidance.

G-POEM / pyloromyotomy coverage

Covered when ALL of the following are met for gastroparesis interventions

G-POEM / pyloromyotomy criteria: Patients with gastroparesis refractory to medical therapy with persistent symptoms may be considered for pyloromyotomy (laparoscopic or endoscopic) when performed in experienced centers; ACG suggests pyloromyotomy over no treatment and AGA offers procedural guidance for G-POEM while noting evidence limitations.failure of standard medical therapy documented

Operator experience and patient selection emphasized; choice of endoscopic versus surgical approach not prescribed.

Safety/durability considerations

Noted limitations and safety outcomes that inform coverage discretion

Safety and durability considerations: Device removal and complications (for example, device removal rates, dysphagia incidence, rare erosion events) and limited long-term comparative data should be considered when evaluating candidates and obtaining informed consent.observational and registry data

Reported device removal ~2.7% in MSAD series; dysphagia incidence ~10% at 1 year with decrease over time; erosion rare but reported.

Proven/Medically Necessary Therapies for Refractory Gastroparesis

Covered when ALL of the following are met (policy-level summary):

GES or pyloroplasty for refractory gastroparesis: Gastric electrical stimulation (GES) therapy and surgical pyloroplasty (open or laparoscopic) are considered proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.failed other therapies documented

This language was relocated into the current policy; detailed patient selection criteria and documentation requirements are in other policy sections.

Endoluminal therapy with the GERDx™ system is classified as investigational and not medically necessary for the treatment of GERD because it has not received U.S. Food and Drug Administration approval and supporting clinical evidence is insufficient to demonstrate safety and effectiveness.

Procedures that lack adequate evidence of clinical benefit, long-term durability, or that are applied outside guideline-recommended indications are considered not proven and may be excluded. Examples include endoscopic therapies, injection or implantation techniques, and procedures supported only by small, heterogeneous studies or short follow-up periods.

Techniques primarily supported by small single-center, retrospective series without long-term outcome data may be excluded or require substantial additional justification; the policy notes limited generalizability of positive findings from tertiary centers and calls for larger, high-quality trials before routine coverage.

Endoscopic plication and suturing procedures have limited-quality evidence, with many studies lacking randomization, control groups, and adequate follow-up; reported trends show symptomatic improvement that diminishes over time (up to 60 months), supporting their characterization as having insufficient evidence for durable benefit.

Injectable bulking agents (for example, Plexiglas and Durasphere) are considered to have insufficient evidence to establish long-term safety and effectiveness for GERD; available data are limited to small case series and do not support these techniques as proven effective.

Use of devices for indications outside their FDA labeling (for example, Enterra® outside its HDE-specified indication) constitutes off-label use and may not be supported without clinical justification; such off-label applications could lead to coverage denial if not adequately documented.

Prior policy language that described functional lumen imaging probe technology as unproven and not medically necessary for diagnosing achalasia has been removed from this policy and is no longer included in the exclusion statements.

G-POEM and other endoscopic GERD therapies, injection techniques, and certain implant procedures are stated as unproven and not medically necessary for treating gastroparesis or GERD when evidence is insufficient; current literature shows short-term benefits in some series but overall evidence quality is low and long-term durability and comparative effectiveness remain unclear.

Gastric electrical stimulation (GES) is not intended for routine use in non-refractory gastroparesis; guideline documents and systematic reviews emphasize GES use for patients with medically refractory diabetic or idiopathic gastroparesis who have failed standard therapies, and note that controlled trial evidence is limited.

Procedures such as Z-POEM, G-POEM, and some endoscopic GERD therapies are considered to have limited evidence; while short-term symptomatic improvement has been reported, the policy highlights the need for larger, controlled, and longer-term studies before these interventions can be considered proven and routinely covered.

Available endoscopic therapies for GERD frequently demonstrate a pattern of progressive loss of symptomatic benefit over time in controlled analyses, with some studies reporting diminishing response by 60 months; this lack of durable control is a key limitation cited for excluding these procedures as proven long-term therapies.

Injectable bulking agents have been reported only in small case series with limited objective outcome data; because of this insufficient and low-quality evidence, these agents are not considered proven effective and safe for GERD and are excluded from coverage as established therapies.

Radiofrequency energy treatment (Stretta) is not recommended by the ACG as a routine replacement for antireflux surgery due to inconsistent and low-quality efficacy data; guideline positions advise against its routine use for standard antireflux replacement.

Text previously stating that functional lumen imaging probe technology was unproven and not medically necessary for diagnosing achalasia has been intentionally removed from the policy; no current exclusional language on that technology appears in the revised sections cited.

Coding and Device Identifiers

Applicable procedure CPT codes (group 1)CPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach

Applicable procedure CPT codes (group 2)CPT

43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open.
43999	Unlisted procedure, stomach.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.

Devices referencedmixed

Enterra®

Implantable gastric electrical stimulator (device name referenced in clinical studies)

No explicit codes listed in this sectionmixed

No codes listed

Procedure codes mentioned (none listed in this excerpt)mixed

No codes listed

FDA PMA / device identifiersmixed

P100049

FDA PMA number referenced for LINX Reflux Management System

FDA HDE / device identifiersmixed

HDE (Enterra)

Humanitarian Device Exemption for Enterra gastric electrical stimulation system

inv-40: Hiatal hernia size (suitability threshold)

Hiatal hernia size thresholdMany device trials and professional statements referenced hiatal hernia size ≤2–3 cm as anatomic eligibility for device-based antireflux procedures (e.g., ASGS statement for TIF; trial inclusion criteria commonly used ≤2–3 cm).

Source examplesASGS position and trial eligibility commonly cite hiatal hernia ≤2 cm (ASGS statement) and LINX/TIF studies reference hernia limits up to 3 cm.

Documentation expectationHiatal hernia size should be documented by endoscopy or imaging as part of pre-procedure objective testing to confirm eligibility.

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization May Be Required

Prior authorization may be required for some procedures and devices described in this policy. Verify member benefits and obtain any required prior authorization before scheduling services.

Prior authorization requirements vary by product and state contract.
Prior authorization may be required for device implantation, endoscopic procedures, and selected surgical interventions.

Prior Authorization

Prior Authorization for Device/Procedure

Prior authorization is often required for implantation of devices or procedures that involve implantable stimulators, sphincter augmentation systems, or other specialized devices. Providers should submit complete clinical documentation to support medical necessity.

Examples include gastric electrical stimulation (Enterra), LINX Reflux Management System (MSA), and other implantable devices.
Include device model, indication, and prior conservative treatments in the request.

Background and Clinical Context

Gastroparesis commonly presents with nausea, vomiting, early satiety and is characterized by objectively confirmed delayed gastric emptying (typically documented by gastric scintigraphy). Clinical management includes dietary and medical therapies first; minimally invasive interventions are considered when symptoms are refractory to standard care.

Definitions and Terms

inv-70: Achalasia definition

DefinitionA primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, resulting in impaired relaxation of the esophagogastric junction (EGJ) and loss of organized peristalsis in the esophageal body.

Clinical relevanceIndication for POEM when authorized: achalasia types I–III where endoscopic myotomy is considered.

Reference society wordingDefinition text cites ASGE terminology and pathophysiology.

inv-71: Diffuse Esophageal Spasm definition

DefinitionRare esophageal motility disorder characterized by simultaneous, uncoordinated, or rapidly propagated contractions of normal amplitude accompanied by dysphagia.

Clinical presentationTypically presents with dysphagia and may be considered an indication for POEM in selected cases.

Policy Revision History

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Tennessee Only)

Policy CodePolicy CS079TN.U

Change TypeMaterial coverage update — GES and pyloroplasty language addedfunctional lumen imaging probe NMN language removed

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization documenting failure of standard therapies and supporting diagnostic tests before requesting coverage for device-based or surgical interventions.

SourceLink

On This Page

mixed trial results and low-quality evidence

Large, multicenter RCTs with long-term outcomes are needed.

Evidence of sustained benefit for the intended duration (device-specific; longer-term data preferred). If only short-term or low-quality evidence exists, coverage should be limited or considered investigational pending further data.

long-term outcome data preferred

Many endoscopic therapies lack high-quality long-term RCT data and show risk of symptom recurrence beyond 3–5 years.

Anatomic considerations: Patient meets device-specific anatomic criteria when specified (for example, hiatal hernia size limits, Hill grade) as required in supporting studies.hiatal hernia ≤2–3 cm when specified

GERDx and TIF trial inclusion often required small hiatal hernia size.

Exclusions based on evidence quality: Procedures with insufficient, low-quality, or non-durable evidence (small nonrandomized case series without objective outcomes) should be considered experimental/investigational and not covered until higher-quality data are available.absence of robust comparative or long-term data

Policy cites small samples, lack of randomization, and short follow-up for many modalities.

Patient counseling on potential benefits, limited long-term durability evidence for some procedures, and procedure-specific risks including dysphagia, need for dilation, device explantation or erosion.

consent documentation

Based on reported adverse events and long-term outcomes for MSA and TIF.

limited or low-quality evidence

Multiple systematic reviews and RCTs show inconsistent or low-quality evidence for many endoscopic GERD therapies.

Prior Authorization

Prior Authorization Likely Required

Prior authorization is likely required for advanced endoscopic or surgical procedures such as G-POEM, POEM, laparoscopic pyloroplasty, and other specialty interventions. Check plan-specific requirements.

Authorization submissions should identify the exact procedure (CPT or unlisted code) and the provider performing the procedure.
Include operative plan and whether the procedure is primary or a revision/removal.

Prior Authorization

Prior Authorization for Endoscopic GERD Procedures

Prior authorization is required for endoscopic procedures intended to treat GERD (e.g., TIF, EsophyX, endoscopic plication) when performed as a therapeutic intervention. Provide objective testing and documentation of failed medical therapy.

Document prior conservative therapy and objective testing (pH monitoring, endoscopy, manometry) when requesting authorization.
Endoscopic GERD procedures without required objective testing may be denied.

Documentation Required

Documentation of Failed Medical Therapy and Objective Testing

Documentation must show failure of appropriate medical therapy and supporting objective testing prior to consideration of device implantation or surgery. Authorization reviewers expect evidence of stepwise escalation of care.

Failed medical therapy: inadequate symptom control despite optimized pharmacologic therapy (e.g., PPIs for GERD, prokinetics/antiemetics for gastroparesis) documented in the record.
Objective testing: relevant results such as gastric emptying study, esophageal pH/impedance testing, endoscopy, and manometry as applicable.

Documentation Required

Medical Record Documentation Requirements

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services. This includes relevant medical history, physical examination findings, diagnostic test results, prior treatments tried, response to therapy, and legible provider notes. Lack of adequate documentation may result in denial of coverage.

Record must be legible and maintained in the patient's medical record and made available upon request.
Include dates, durations, dosages of medications, duration of symptoms, and attempts at conservative management.
Attach prior imaging, study reports (e.g., gastric emptying study, pH testing), and consult notes when available.

Documentation Required

GES and Pyloroplasty Sequencing Note

GES and pyloroplasty are indicated after failure of appropriate medical and conservative therapies for gastroparesis. Authorization requests for GES or surgical pyloroplasty should document prior stepwise treatments and why less invasive options were insufficient.

Document prior conservative therapy such as dietary modifications, prokinetic agents, antiemetics, pyloric Botox if used, and nutritional support.
Indicate duration of symptoms and failure to respond to optimized medical therapy before proceeding to GES or pyloroplasty.
Refer to FDA HDE labeling for Enterra when applicable and include applicable FDA device information in the submission.

Step Therapy

Conservative Therapy Before Device or Surgery

Conservative therapy should be attempted and documented prior to device implantation or major surgery. Reviewers expect evidence of trials of medical management and, where applicable, less invasive procedural options.

Conservative measures include diet modification, medication optimization, and outpatient management strategies.
Document dates, agents (including doses), and duration of trials.

Step Therapy

Step Therapy Expectation for G-POEM

For G-POEM, expect step therapy: G-POEM is considered only after failure of optimized medical therapy and, where appropriate, prior pyloric-directed therapies. Documentation should clearly show prior treatment attempts and objective testing.

Include results of gastric emptying study and symptom scores (e.g., GCSI) when available.
If prior pyloric therapies (e.g., endoscopic or surgical pyloroplasty, pyloric Botox) were performed, provide details and outcomes.

Documentation Required

Confirm Prior Medical Therapy

Confirm prior medical therapy in the medical record for any request for advanced interventions for gastroparesis or GERD. The record must detail therapies tried and response to those therapies.

Explicitly document trials of prokinetics, antiemetics, dietary interventions, and adherence.
For GERD procedures, document PPI trial duration and objective testing results.

Denial Risk

Failure of Medical Therapy Documentation

Providers must document failure of medical therapy when seeking authorization for advanced procedures. Incomplete documentation of prior failures or absence of objective testing increases the risk of denial.

Failure of medical therapy should include specific timeframes and outcomes (e.g., persistent symptoms despite X weeks/months of therapy).
If documentation is not provided or is insufficient, the request may be denied as not meeting medical necessity criteria.

Prior Authorization

Device-Specific Prior Authorization

Device-specific prior authorization may be required for off-label or non-FDA labeled uses. When requesting coverage for off-label device use, include rationale and supporting evidence in the medical record.

Identify whether device use aligns with FDA labeling (e.g., Enterra HDE indications) and note any deviations.
Provide literature or specialty society guidance if proposing off-label device use.

Note

Coverage Determination and Prior Authorization

Coverage determinations and prior authorization reviews are governed by the member’s benefit plan, applicable federal/state law, and contractual terms. Inclusion of a code in the policy does not guarantee coverage or payment; prior authorization and supporting documentation are required.

Ensure authorization requests reference applicable CPT/HCPCS codes and include all requested documentation.
Benefit coverage is subject to plan limitations, exclusions, and member eligibility at the time of service.

Source attributionDefinition referenced to National Library of Medicine terminology in policy definitions section.

inv-72: GERD definition

DefinitionA condition in which the lower esophageal sphincter (LES) relaxes too often or weakens, allowing stomach acid to reflux backward into the esophagus.

Clinical implicationsMay lead to esophagitis or Barrett's esophagus; objective testing (pH, endoscopy) often used to document disease for procedural candidacy.

AuthorityDefinition cited from American College of Gastroenterology (ACG) wording in the policy.

inv-73: Gastroparesis definition

DefinitionA digestive disorder in which gastric motility is abnormal or absent, also known as delayed gastric emptying.

Common symptomsPresents with nausea, vomiting, early satiety, and bloating; objective confirmation often by gastric emptying scintigraphy.

Etiologies notedIncludes diabetic, idiopathic, medication-induced, or postsurgical causes; etiology informs therapy selection.

inv-74: GES (Gastric Electrical Stimulation) definition

DefinitionAn implanted neurostimulation device (e.g., Enterra®) used as a humanitarian use device to reduce symptoms in medically refractory diabetic or idiopathic gastroparesis.

Use contextConsidered for refractory/intractable nausea and vomiting after failure of standard therapy and typically when patients are not using opioids (per AGA guidance).

Regulatory noteGES has Humanitarian Device Exemption (HDE) labeling referenced in policy FDA section.

inv-75: POEM definition

DefinitionPer oral endoscopic myotomy (POEM) is an endoscopic myotomy procedure used to treat esophageal achalasia, with randomized trial evidence demonstrating noninferiority to laparoscopic Heller myotomy plus fundoplication.

Procedure contextPerformed by physicians with formal POEM training; outcomes in trials assessed by validated symptom scores (Eckardt).

Evidence summaryWerner et al. RCT reported 2-year clinical success ~83% for POEM in achalasia patients.

inv-76: Z-POEM definition

DefinitionZenker's peroral endoscopic myotomy (Z-POEM) is an endoscopic myotomy technique applied to Zenker's diverticulum.

Evidence limitationsPublished literature is limited in quality and size; long-term comparative effectiveness, recurrence, and reintervention data are insufficient.

Clinical roleMay be considered in expert centers as an alternative to flexible endoscopic septotomy, with short-term outcomes appearing comparable in observational series.

inv-77: Z-POEM alternate entry

Alternate wordingZ-POEM: peroral endoscopic myotomy for Zenker's diverticulum; current evidence base consists largely of retrospective, single-center studies and a recent meta-analysis of observational comparisons to FES.

Research needFurther prospective, long-term comparative data are required to establish safety and durability.

Practical noteClinical success definitions vary across studies; operator experience influences outcomes.

inv-78: G-POEM definition

DefinitionGastric peroral endoscopic myotomy (G-POEM) is an endoscopic pyloric myotomy technique developed for treatment of refractory gastroparesis.

Evidence statusAvailable studies show short-term clinical benefit in many series, but overall evidence quality is insufficient to confirm long-term safety and efficacy and generalizability is limited.

Patient heterogeneityEtiologic heterogeneity (diabetic, idiopathic, medication-induced, postsurgical) and variable success definitions complicate interpretation of outcomes.

inv-79: Stretta definition

DefinitionStretta is an endoscopic radiofrequency energy therapy intended to treat GERD by delivering thermal lesions that promote scarring and tightening around the LES.

Evidence summaryRandomized and nonrandomized studies provide mixed results; overall evidence quality is low with uncertainty about comparative effectiveness versus fundoplication.

Guideline stanceACG does not recommend Stretta as a routine replacement for antireflux surgery due to inconsistent efficacy data.

inv-80: Endoscopic fundoplication / TIF / EFTP definition

DefinitionEndoscopic fundoplication (including TIF and EFTP) are endoluminal procedures that reconstruct or tighten the gastroesophageal valve to reduce reflux.

Devices/techniquesIncludes EsophyX (TIF), full-thickness endoscopic fundoplication (EFTP), and other device-based endoscopic approaches evaluated in RCTs and observational studies.

Evidence notesRCTs and systematic reviews show symptom improvement and PPI reduction for TIF/EFTP in selected patients, but long-term durability and patient selection criteria vary across studies.

inv-81: TIF definition

DefinitionTransoral incisionless fundoplication (TIF) performed with the EsophyX system creates a fundoplication via an endoscopic transoral approach to reduce reflux.

Study populationsTypically studied in adults with chronic or refractory GERD, often with hiatal hernia ≤2–3 cm and without severe esophagitis.

Outcomes summarySystematic reviews report symptom improvement and reduced PPI use at 6–12 months; some long-term series report sustained satisfaction up to 5 years in selected cohorts.

inv-82: MSA (LINX) definition

DefinitionMagnetic sphincter augmentation (MSA, LINX) is a laparoscopically implanted ring of magnetic beads placed around the LES to augment sphincter function.

Clinical outcomesStudies report high rates of PPI discontinuation and symptom improvement, but potential risks include postoperative dysphagia, need for dilation, device explantation, and rare erosion.

Regulatory/ evidence noteRCTs and multiple observational studies exist; long-term comparative data and adverse event characterization continue to be evaluated.

inv-83: Injectable bulking agents definition

DefinitionInjectable bulking agents (e.g., Durasphere, Plexiglas) are materials injected into the gastroesophageal junction to bulk the area and reduce reflux.

Evidence limitationsEvidence is limited to small case series with insufficient data to establish long-term safety and effectiveness; randomized trials are lacking.

Policy stancePolicy states these techniques have insufficient evidence and are considered investigational pending further study.

inv-84: MSA / LINX alternate definition

Alternate wordingMSA/LINX: laparoscopic implantation of a magnetic ring to augment LES barrier function; associated with high rates of PPI cessation but with recognized risks (dysphagia, explantation, rare erosion).

Evidence nuanceSystematic reviews/meta-analyses include RCT and many observational studies; calls for more high-quality comparative trials remain.

Practical documentationPreoperative evaluation in LINX studies typically included abnormal pH testing, hiatal hernia assessment, and absence of advanced esophagitis for selected candidates.

inv-85: G-POEM (definition repeat)

Definition (repeat)G-POEM is an endoscopic pyloric myotomy technique for refractory gastroparesis; considered safe with high technical success in experienced centers but evidence on long-term efficacy remains limited.

Guideline contextAGA practice update notes G-POEM is safe in experienced hands; ACG provides conditional recommendation supporting pyloromyotomy approaches for refractory gastroparesis.

Evidence cautionRandomized data are limited (one small RCT) and larger, longer-term trials are needed to define patient subgroups most likely to benefit.

inv-86: Gastroparesis definition updated note

Updated definition notePolicy updated the gastroparesis definition within the document: gastroparesis is delayed gastric emptying due to abnormal or absent gastric motility; detailed updated wording is included in policy definitions.

Clinical implicationUpdated definition supports coverage statements for GES and pyloroplasty for refractory gastroparesis when other criteria are met.

ReferenceDefinition text cites Camilleri (2013, updated 2022) and policy revision history notes inclusion of updated definitions.